| Vaccine | No Adjuvant |  |
---|---|---|---|
 | N = 67 | N = 123 |  |
 | N(%)/Mean(SD) | N(%)/Mean(SD) | P-Value |
Age | 56.00 (13.44) | 60.05 (16.44) | 0.086 |
Sex | Â | Â | 0.2854 |
 Female | 31 (46.27) | 47 (38.21) |  |
 Male | 36 (53.73) | 76 (61.79) |  |
Thicknessa | 3.12 (4.43) | 4.18 (4.46) | 0.009 |
Ulceration | Â | Â | 0.3511 |
 Present | 23 (34.33) | 52 (42.28) |  |
 Absent | 32 (47.76) | 57 (46.34) |  |
 Undetermined | 12 (17.91) | 14 (11.38) |  |
AJCC Stage | Â | Â | 0.0082 |
 IIIA | 15 (22.39) | 48 (39.02) |  |
 IIIB | 26 (38.81) | 51 (41.46) |  |
 IIIC | 26 (38.81) | 24 (19.51) |  |
Histologic Subtype | Â | Â | 0.0435 |
 Nodular | 17 (25.37) | 52 (42.28) |  |
 Superficial Spreading | 12 (17.91) | 26 (21.14) |  |
 Other | 6 (8.96) | 13 (10.57) |  |
 Undetermined | 32 (47.76) | 32 (26.02) |  |
Other Adjuvant Treatment |  |  | – |
 GM-CSF | 6 (8.96) | Not Applicable |  |
 Interferon | 6 (8.96) |  | |
 Isolated Limb Infusion | 3 (4.48) |  | |
 Radiation | 22 (32.84) |  |